AstraZeneca’s Ready-Made Immune System Receives Approval to Register in Thailand for RSV Prevention in High-Risk Children
New Drug Approved in Thailand to Protect Children from RSV Virus RSV virus: The RSV virus is a major cause of lower respiratory tract infections in children worldwide. More than 90% of children under the age of two have been affected by this virus. According to the World Health Organization (WHO), the RSV virus is […]
Shortage of New RSV Vaccine ‘Beyfortus’ Highlights Need for Priority Vaccination
Shortage of New RSV Vaccine “Beyfortus” in US Doctors in the United States have been advised to prioritize the new infant vaccine “Beyfortus” against respiratory syncytial virus (RSV) for babies most at risk of serious disease, as the drug is currently in short supply, according to the Centers for Disease Control and Prevention (CDC). Priority […]
Forxiga Reveals Results of DAPA-MI Study at AHA 2023
Forxi unveils the findings of the ‘DAPA-MI study’ at AHA 2023 Forxi, a product developed by AstraZeneca, has shown an additional benefit in the treatment of heart disease. The widely prescribed drug known for its effectiveness in treating type 2 diabetes and heart failure, Farxiga (dapagliflozin), has been found to improve various cardiovascular indicators in […]
AstraZeneca Thailand and Bangkok Partner to Increase Lung Cancer Survival Rates by 2025
AstraZeneca Thailand Collaborates with Bangkok to Improve Lung Cancer Survival Rates This landmark collaboration between AstraZeneca Thailand and Bangkok is seen as a significant effort to advance the mission of The Lung Ambition Alliance (LAA). The LAA, which comprises AstraZeneca, the Cancer Coalition of Global Lung (GLCC), Guardant Health, and the International Association for the […]
Bangkok and AstraZeneca Join Forces to Boost Lung Cancer Screening Efficiency with AI Technology
AstraZeneca Partners with Bangkok to Utilize Artificial Intelligence Technology for Early Lung Cancer Screening In an effort to reduce the alarming death rate of lung cancer in Thailand, AstraZeneca and Bangkok have signed a memorandum of understanding, expressing their commitment to cooperate in the use of artificial intelligence (AI) technology. The primary goal of this […]
AstraZeneca Raises Concerns Over Yuhan’s Patient Attraction Tactics for Lexraza
Concerns raised over Yuhan’s decision to provide free Lexraza AstraZeneca highlights potential impact on government reimbursement AstraZeneca, the manufacturer of Tagrisso (osimertinib), a therapeutic drug competing for reimbursement as first-line treatment, has expressed concerns over Yuhan Corporation’s decision to supply Lexraza free of charge. The company fears that this move may weaken the government’s willingness […]
Yuhan’s Lexraza: A Patient-Oriented Strategy or Market Takeover?
Yuhan Corporation’s Early Access Program for Lexraza: A Patient-Centric Approach or Marketing Strategy? In a recent press conference, Cho Wook-je, the CEO of Yuhan Corporation, announced the company’s entry into the Early Access Program (EAP) for Lexraza, a frontline treatment for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer. However, he emphasized […]
Yuhan Corporation’s Free Supply of Lexraza: A Strategic Move or Patient-Centric Choice?
Yuhan’s Lexraza: A Patient-Centered Approach or Market Strategy? In a recent press conference, Cho Wook-je, the CEO of Yuhan Corporation, announced the company’s decision to launch an Early Access Program (EAP) for Lexraza, a first-line treatment for non-small cell lung cancer. However, the CEO emphasized that the program was not aimed at attracting patients but […]
AstraZeneca’s ‘Imfinzi’ Receives First-Line Indication for Hepatocellular Carcinoma Combination Therapy with Imudo
AstraZeneca Korea, headed by CEO Kim Sang-pyo, has announced that its anti-PD-L1 immuno-oncology drug, ‘Imfinzi (Dervalumab),’ has received approval from the Ministry of Food and Drug Safety for an additional indication as a first-line treatment option for advanced or unresectable hepatocellular carcinoma. This approval was granted based on the findings from the phase 3 HIMALAYA […]
Food and Drug Safety Administration, Forxiga generic ‘Sim Shin’ ad “No”
The Ministry of Food and Drug Safety “Using advertisements other than approved signs is contrary to the Pharmaceutical Affairs Act” response AstraZeneca “Encouraging prescriptions for indications other than approval, even off-label” A generic pharmaceutical company said “clearly the ingredients are effective and effective, there is no problem” Forxiga generic drug brochure. The efficacy and effectiveness […]
